CORRECTED-Lexicon expects delay in FDA feedback on additional data for its diabetes drug
Sept 22 (Reuters) - Lexicon Pharmaceuticals LXRX.O said on Monday the U.S. Food and Drug Administration requires more time to review the company's previously submitted additional data on its experimental drug, Zynquista, for patients with type 1 diabetes.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Tesla Opens Up Over 2%, Shares Return to $400, Here Is What Investors Need to Note

Why SanDisk Stock Could Soar to $4,000?

SpaceX IPO Approaches: Musk Dissolves xAI into SpaceX and Subleases 300MW Compute to Anthropic; Can the $2 Trillion Valuation Hold?

US-Iran Tensions Heat Up Again, Brent Crude Prices Return Above $100

Trump Administration Brokers. Intel and Apple Reach Chipmaking Agreement, Shares Surge More Than 13%

Tradingkey







